Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients.

Sander BinsAlwin D R HuitemaPim LavenSamira El BouazzaouiHuixin YuNielka van ErpCarla van HerpenPaul HambergHans GelderblomNeeltje SteeghsStefan SleijferRon H N van SchaikRon H J MathijssenStijn L W Koolen

Published in: Clinical pharmacokinetics (2020)

This analysis shows that CYP3A4*22 heterozygotes have a substantial lower pazopanib clearance and that dose adjustments based on CYP3A4*22 status could be considered.

Keyphrases

data analysis